Targeting TGF-b pathway with COVID-19 Drug Candidate ARTIVeda/PulmoHeal Accelerates Recovery from Mild-Moderate COVID-19. Learn more >
Artemisinin for COVID-19: Indian and US firms launch clinically tested supplement after ayurvedic regulatory approval. Learn more >
Saran Saund, Chief Business Officer, and General Manager of the AI division, of Mateon-Oncotelic Therapeutics, talked about how India is using technology to fight COVID-19. Watch the interview on Youtube HERE.
Empowered Patient Podcast
COVID-19 Therapy Based on AI Pharmaceutical Biotech and Ethnobotanicals with Dr. Saran Saund Oncotelic Therapeutics. Listen to the podcast HERE. Download the transcript HERE.
Ayurveda, Artemisia, and Covid-19
December 16, 2020 7AM PST – 10AM EST – 8:30PM IST
Featuring Global Experts in Ayurveda and Pharmacology. Learn more >
POSITIVE EARLY RESULTS FOR ARTIVEDATM IN TREATING COVID-19. Learn more >
Oncotelic is an immuno-oncology company dedicated to the development of first in class RNA therapeutics as well as small molecule drugs against cancer and infectious diseases. OT-101, the lead immuno-oncology drug candidate of Oncotelic, is a first-in-class anti-TGF-βRNA therapeutic that exhibited single agent activity in relapsed/refractory cancer patients in clinical trial settings. OT-101 also has activity against SARS-CoV-2. Mateon/Oncotelic is seeking to leverage its deep expertise in drug development to improve treatment outcomes and survival of cancer patients with a special emphasis on rare pediatric cancers. Mateon has rare pediatric designation for DIPG (OT-101), melanoma (CA4P), and AML (OXi4503).